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Abstract  
 
 
Studying the phenotypic manifestations of increased genetic liability for schizophrenia can 
increase our understanding of this disorder. Specifically, information from alleles identified 
in genome-wide association studies can be collapsed into a polygenic risk score (PRS) to 
explore how genetic risk is manifest within different samples. In this systematic review, we 
provide a comprehensive assessment of studies examining associations between 
schizophrenia PRS (SZ-PRS) and several phenotypic measures. We searched EMBASE, 
Medline and PsycINFO (from August 2009 – 14th March 2016) plus references of included 
studies, following PRISMA guidelines. Study inclusion was based on predetermined criteria 
and data were extracted independently and in duplicate. Overall, SZ-PRS was associated 
with increased risk for psychiatric disorders such as depression and bipolar disorder, lower 
performance IQ and negative symptoms. SZ-PRS explained up to 6% of genetic variation in 
psychiatric phenotypes, compared to less than 0.7% in measures of cognition. Future gains 
from using the PRS approach may be greater if used for examining phenotypes that are 
more closely related to biological substrates, for scores based on gene-pathways, and where 
PRSs are used to stratify individuals for study of treatment response. As it was difficult to 
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interpret findings across studies due to insufficient information provided by many studies, 
we propose a framework to guide robust reporting of PRS associations in the future.   
 
Key words: polygenic risk score, schizophrenia, genetic, phenotypes 
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1. Introduction 
 
Schizophrenia (SZ) is highly heritable (Sullivan et al. 2003). The importance of studying the 
phenotypic manifestations of increased schizophrenia liability has long been recognized as a 
way to increase our understanding of this disorder. However, until recently, such research 
has been limited to small studies of individuals at high risk as indexed by having a family 
history (Niemi et al. 2003).  
 
Genome-wide association studies (GWAS) of schizophrenia have now identified multiple risk 
variants (Purcell et al. 2009; Ripke et al. 2014), and although individual loci have small 
effects on risk, information from even moderately associated alleles can be collapsed into a 
single polygenic risk score (PRS) to explore how genetic risk is manifest across different 
populations or stages of development (Figure 1) (Wray et al. 2014).  
 
Since this approach was first described, many studies have examined whether SZ-PRS is 
associated with a diverse range of phenotypes. To summarise this literature, we conducted 
a systematic review to identify studies that have used a PRS approach to examine 
phenotypes associated with genetic risk for schizophrenia.
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2. Methods 
 
We undertook a systematic review following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al. 2009) (Supplementary Table 
1). 
 
2.1 Search strategy  
 
2.1.1 Inclusion/exclusion criteria  
 
We included articles that examined associations between a PRS (derived from GWAS data of 
participants with schizophrenia) and a measurable phenotype (excluding neuroimaging 
outcomes). Articles reporting associations with a diagnosis of schizophrenia as an outcome 
were not included. Articles were required to be published in peer-reviewed journals in 
English (see Supplementary Table 2 for inclusion/exclusion criteria).  
 
2.1.2 Data sources 
 
We searched EMBASE, Medline and PsychINFO from 06/08/2009 to 14/03/2016, and hand-
searched references of included articles. 
 
2.1.3 Search terms and delimiters  
 
We searched for articles using the terms “schizophrenia (or variations of)” AND “polygenic 
(or variations of)”. Full search strategy terms are listed in Supplementary List 1.   
 
2.1.4 Data collection and analysis 
 
2.1.4.1 Selection of studies 
 
There were 1043 articles after de-duplication (Figure 2). Titles and abstracts were initially 
screened by one author (S.M.). If it was unclear whether the paper contained relevant data, 
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or the abstract was not available, the full-text article was retrieved. Full-text articles were 
reviewed and checked against inclusion criteria by two authors independently. 
Disagreements were resolved by a third author. Relevant data were extracted using a data 
extraction form (Supplementary table 3). Results were summarised using a narrative 
approach because most studies did not report results in a format comparable with other 
studies.
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3. Results 
 
Thirty-one articles examined the association between SZ-PRS and a measurable phenotype. 
Most studies used the Psychiatric Genetics Consortium-1 SZ (PGC-1-SZ) discovery sample 
and reported associations at different PT values (Supplementary Tables 4a-4e). 
 
3.1 Non-schizophrenia psychosis diagnoses  
 
A higher SZ-PRS was found in schizoaffective compared to non-schizoaffective bipolar 
disorder within the Wellcome Trust Case-Control Consortia (WTCCC) (PT<0.5; one-tailed 
p=5x10-4), and replicated using University College London Bipolar Disorder (UCL-BD) sample 
data (one-tailed p=0.007) (Hamshere et al. 2011).  
             
In a Norwegian sample, the SZ-PRS was higher in those with bipolar I disorder (strongest 
PT<0.05; p =3.1x10-5), schizoaffective disorder (p=7.4x10-3), and psychosis-NOS (p= 0.016) 
compared to controls without SZ, BD or MDD (Tesli et al. 2014).  
 
In another study, the SZ-PRS was reported as not associated with psychosis history in 
individuals with BD, though no statistics were provided (Ruderfer et al. 2014). 
 
3.2 Schizophrenia symptoms/severity  
 
In the Netherlands case-control study of schizophrenia, SZ-PRS was associated with five 
symptom dimensions (strongest PT<0.5): positive  (p=<0.01), negative (p= <0.001), mania (p= 
<0.01), depression (p= <0.001) and disorganisation (p=0.04) within the combined case-
control sample, but not with these dimensions in cases and controls examined separately 
(Derks et al. 2012). 
 
In data from the Molecular Genetics of Schizophrenia sample, SZ-PRS was associated with 
the negative/disorganized factor (strongest PT<0.5, p=0.006), but not with the positive 
symptoms or mood factors (Fanous et al. 2012). 
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The population-based Longitudinal Experiences and Perceptions (LEAP) study found that SZ-
PRS was associated with decreased anhedonia (strongest PT<0.5; one-tailed p=0.003) and 
parent-rated negative symptoms in adolescence (one-tailed p=0.029) (Sieradzka et al. 2014).   
 
In another population cohort, the Avon Longitudinal Study of Parents and Children 
(ALSPAC), there was weak evidence that SZ-PRS was associated with increased adolescent 
psychotic experiences (strongest PT<0.3; p=0.134). However, a PRS derived from the 17 
genome-wide significant single nucleotide polymorphisms (SNPs) published at the time was 
associated with reduced odds of psychotic experiences (p=0.024) (Zammit et al. 2014).  
 
A further ALSPAC study used the larger PGC-2-SZ discovery sample and reported that SZ-PRS 
(PT<0.05) was associated with adolescent negative symptoms (p=0.001) and anxiety disorder 
(p=0.002), but not with depression (p=0.77) or psychotic experiences (p=0.14) (Jones et al. 
2016).  
 
A study from the Centre for Addiction and Mental Health found no evidence of association 
between SZ-PRS and antipsychotic dosage (e.g. defined daily dosage: PT<0.01; p=0.512) or 
global assessment of functioning (p=0.550) (Hettige et al. 2016). 
 
One study reported higher SZ-PRS in individuals with schizophrenia with a history of 
clozapine treatment, compared to those without (strongest PT<0.5; 1-tailed p=0.02), as well 
as in those who responded to clozapine compared to those who did not (1-tailed p=0.06) 
(Frank et al. 2015).  
 
3.3 Other psychiatric disorders  
 
A study using data from the PGC reported the SZ-PRS was associated with BD (strongest 
PT<0.3; p=1x10-16), depression (p=1x10-16), and Autism Spectrum Disorder (ASD) (strongest 
PT<0.001; reported as p= <0.05), but not with ADHD at any PT (Cross-Disorder Group of the 
Psychiatric Genomics 2013). There was also weak evidence supporting an association with 
ASD in the Autism Genome Project (strongest PT<0.01; p=0.08) (Vorstman et al. 2013), and 
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strong evidence of association with depression (strongest PT<0.1; p=8.3x10-12), severe 
atypical (p=7.8x10-5) and typical (strongest PT<0.5; p=7.8x10-9) depression in combined data 
from two Netherlands-based samples (Milaneschi et al. 2016).    
 
SZ-PRS was also associated with BD in two other studies: one using data from the STEP-BD 
and WTCCC-BD samples (strongest PT<0.5; p=7x10-9 and p=1x10-12 respectively) (Purcell et 
al. 2009), and another also using data from the WTCCC but using the larger PGC-2-SZ 
discovery sample (PT<1; p=3.7x10-47) (Stringer et al. 2014).  
 
Inconsistent with the results from the PGC described above, a study using data from 
adolescents in Dublin, UK, reported a higher SZ-PRS in ADHD cases compared to controls 
(PT<0.5; p=1.04x10-4) (Hamshere et al. 2013).  
 
SZ-PRS was not associated with post-traumatic stress disorder (PTSD) across any PT in the 
Marine Resiliency Studies (Nievergelt et al. 2015).  
 
3.4 Cognition 
 
Higher SZ-PRS was associated with lower total IQ in a combined schizophrenia case–control 
sample (strongest PT<0.3, p=8x10-4), but this was attenuated when analysing cases only 
(p=0.067), with no association in controls (van Scheltinga et al. 2013). Higher SZ-PRS was 
also associated with worse cognitive ability in people with schizophrenia within the 
Cognitive Genomics Consortium (strongest PT< 0.5, p=1.4x10-4) (Lencz et al. 2014). 
 
Higher SZ-PRS was also associated with poorer cognitive ability in two population-based 
samples: i) the Lothian birth cohort (Moray House Test (MHT) of cognitive ability at age 70, 
strongest PT <0.1, p=0.08; Wechsler non-verbal subtests, strongest PT <0.5, p=0.005), and ii) 
the ALSPAC birth cohort (performance IQ, strongest PT <0.1, p=6.07x10-4; total IQ, p=0.008) 
(Hubbard et al. 2016). 
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Furthermore, higher SZ-PRS was also associated with greater decline in IQ with age in the 
Lothian birth cohort (MHT, strongest PT<0.01, p=0.03; Wechsler non-verbal subtests, 
p=0.003) (McIntosh et al. 2013). 
 
However, it is notable that not all findings were consistent across different samples, ages or 
measures. In the Lothian birth cohort, there was no evidence of association between SZ-PRS 
and IQ at age 11 years (strongest PT<0.5, p=0.22) (McIntosh et al. 2013), whilst in the 
ALSPAC study, there was very weak evidence of association with verbal IQ (strongest 
PT<0.0001, p=0.119) (Hubbard et al. 2016). Furthermore, in the Athens Study of Psychosis 
Proneness, there was no association between SZ-PRS and non-verbal IQ or the verbal n-back 
test (no statistics reported) and weak evidence of association with shorter sustained 
attention (strongest PT <0.5; 1-tailed p=0.045) and poorer spatial working memory accuracy 
(1-tailed p=0.044) (Hatzimanolis et al. 2015).  
 
Higher SZ-PRS in individuals with schizophrenia was associated with lower pre-pulse 
inhibition (PPI) in the Learning on Genetics of Schizophrenia study (strongest PT<0.05, 
p=0.005) (Roussos et al. 2015), and with lower auditory steady-state response (ASSR) 
gamma oscillation (strongest PT<1x10-5, p=0.003), but not with other event-related potential 
phenotypes (P3 latency, P3 amplitude or P50 ratio) across any PT in another study (Hall et al. 
2015). 
 
3.5 Other phenotypes 
 
For other phenotypes, higher SZ-PRS was associated with: i) increased creativity (strongest 
at PT<0.2, p=5.2x10-6), years in school (p=1.2x10-4) and obtaining a university degree 
(p=0.014) within an Icelandic general population study (Power et al. 2015); ii) higher 
seasonality score, indexing risk for seasonal affective disorder (strongest at PT<0.5, 
p=1.61x10-15) within the Australian Twin Registry (ATR) and Midwest Alcohol Research 
Centre data (Byrne et al. 2015); iii) lifetime cannabis use (strongest PT< 0.01, p=2.6x10-4) also 
using ATR data (Power et al. 2014); iv) family history of psychotic illness in individuals with 
SZ using PGC data (strongest PT<0.4 (1-tailed-p=0.003) (Bigdeli et al. 2015); v) in individuals 
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with BD with psychosis compared to without psychosis in the WTCCC (PT<0.5; p=0.092), but 
not in the UCL-BD sample (p=0.232) (Hamshere et al. 2011); and vi) with reduced risk of 
suicide attempts in individuals with depression from four independent samples (strongest 
PT<0.05, p=0.05) (Mullins et al. 2014). 
 
3.6 Non-psychiatric disorders 
 
Higher SZ-PRS was not (or only very weakly associated with physical health disorders in a 
study using WTCCC data (strongest PT<0.5: coronary artery disease p=0.71; Crohn’s disease 
(CD) p=0.05; hypertension p=0.3; rheumatoid arthritis (RA) p=0.65; type I diabetes (T1D) 
0.23; type II diabetes (T2D) p=0.06 (Purcell et al. 2009). Another study also using the WTCCC 
RA sample reported only weak evidence of association with RA (strongest PT<0.01, p=0.085) 
(Euesden et al. 2015). 
 
Another study reported much stronger evidence of association between the SZ-PRS and 
physical disorders using WTCCC data, but using the larger PGC-2-SZ discovery sample: T1D 
(p=2.8x10-11), CD (p=1.4x10-9), RA (p=1.8x10-11) and T2D (p=5.7x10-5), all compared to 
controls at PT<1. The SZ-PRS also differed between immune cases (T1D, CD and RA 
combined), BD cases and T2D cases (p= <0.05); between immune cases and BD cases (p= 
<0.05); and between immune cases and T2D cases (p= <0.05), though how these groups 
differed was not specified (Stringer et al. 2014). 
 
Finally, a USA-based study reported no association between the SZ-PRS and Parkinson’s 
disease, although no statistics were reported (Schulze et al. 2014).  
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4. Discussion  
 
To the best of our knowledge, this is the first paper to systematically review how SZ-PRS is 
associated with a wide range of phenotypic outcomes, although other reviews have covered 
PRS methodology and some have included studies of SZ-PRS (Wray et al. 2014). 
 
Higher SZ-PRS was associated with increased risk of several different psychopathologies. 
Typically, R2 values for other psychiatric disorders was greatest (1%-6%), whereas values for 
schizophrenia symptoms and cognitive phenotypes were smaller (<0.7%).  
 
4.1 Psychiatric disorders  
 
There was consistent evidence in at least two studies of higher SZ-PRS in individuals with 
BD, schizoaffective bipolar disorder, (Hamshere et al. 2011; Tesli et al. 2014) and depression 
(Cross-Disorder Group of the Psychiatric Genomics 2013; Milaneschi et al. 2016). This is 
consistent with epidemiological evidence of substantial comorbidity across these disorders 
in population-based registers (Laursen et al. 2009), as well as genetic overlap (Craddock et 
al. 2006; Cardno and Owen 2014). Elevated genetic risk for schizophrenia in those with 
depression has been documented more recently (Power et al. 2017; Verduijn et al. 2017), 
plus greater suicide attempts in individuals with depression (Sokolowski et al. 2016), 
contrary to the findings by Mullins et al. (2014) reported here. 
 
One study in our review reported an association between genetic risk for schizophrenia and 
anxiety disorder, consistent with reports of comorbidity between schizophrenia and anxiety 
(Braga et al. 2013; Young et al. 2013). 
 
In our review, the SZ-PRS was not consistently associated with ADHD, and although 
epidemiological evidence suggests that the risk of developing schizophrenia is elevated in 
individuals with ADHD (Keshavan et al. 2005; Keshavan et al. 2008; Pallanti and Salerno 
2015), the SZ-PRS only captures common genetic variation (Thapar et al. 2016).  
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4.2 Schizophrenia symptoms 
 
One of the main advantages of the PRS approach is the ability to study how genetic risk for 
schizophrenia is manifest across the general population, and during different stages of 
development. This is best exemplified by studies that have examined schizophrenia-related 
psychopathology and cognition as phenotypes.  
  
In two independent population-based samples there was a lack of evidence to support the 
presence of a higher SZ-PRS in individuals who had experienced positive psychotic 
symptoms (Sieradzka et al. 2014; Zammit et al. 2014; Jones et al. 2016). This suggests that 
genetic risk for schizophrenia might be manifest more strongly by other psychopathology 
during adolescence, with positive psychotic experiences only becoming manifest at a later 
age. Perhaps SNPs identified in GWAS of schizophrenia more strongly index other 
characteristics of schizophrenia, such as negative symptoms, that might be selected for in 
clinical samples, as opposed to population-based samples.  
 
Evidence for association with negative symptoms was inconsistent: studies reported both an 
increase (Jones et al. 2016) and a decrease (Sieradzka et al. 2014) in negative symptoms in 
those with higher SZ-PRSs in two population-based cohorts. However, it is difficult to define 
and measure negative symptoms in general population samples. This makes it difficult to 
know to what extent these studies reflect negative symptoms as assessed in clinical samples 
of individuals with schizophrenia. Studies of clinical samples have been more consistent, 
with two studies reporting more negative symptoms in those with a higher SZ-PRS (Derks et 
al. 2012; Fanous et al. 2012; Jones et al. 2016).  
 
4.3 Cognition 
 
The SZ-PRS was consistently associated with poorer cognition in population-based studies 
and from childhood through to older age (McIntosh et al. 2013; Hubbard et al. 2016). There 
was some inconsistency as to which aspects of cognition were most strongly related to 
schizophrenia genetic risk, though more recently published studies support an association 
with general cognitive deficits e.g. IQ (Liebers et al. 2016; Benca et al. 2017). However, in a 
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study of the Icelandic general population, a higher SZ-PRS was associated with greater 
number of years in education and having a university degree (Power et al. 2015), which 
seems, at face value to be contrary to the findings for measures of cognition, and to 
epidemiological studies that show consistent evidence that individuals with lower IQ have 
an increased risk of developing SZ (Zammit et al. 2004; Khandaker et al. 2011). 
 
The associations between SZ genetic risk and some event-related potential measures lends 
support to the body of evidence proposing these as endophenotypes for SZ (Shin et al. 2011; 
Onitsuka et al. 2013). However, whilst GWASs of endophenotypes could theoretically inform 
schizophrenia gene-discovery, similarly large samples as those in current schizophrenia 
GWAS consortia are likely to be required (Hall and Smoller 2010). 
 
 
4.4 Non-psychiatric disorders 
 
The SZ-PRS was also associated with a number of other, non-psychiatric outcomes, including 
diabetes, RA and CD (Stringer et al. 2014), though results were not consistent across studies. 
This is likely to be due to the larger PGC-2-SZ discovery sample used by Stringer et al. (2014). 
These associations are consistent with increasing evidence that inflammation plays a causal 
role in the aetiology of SZ (Jones et al. 2005), and with epidemiological evidence of 
increased incidence of immune disorders in people with schizophrenia (Eaton et al. 2006; 
Eaton et al. 2010), although this evidence is also not entirely consistent (Chen et al. 2012). 
 
4.5 Implications 
 
Overall our results support other approaches that show pleiotropy between schizophrenia 
and other disorders, and suggest there is less common-variant genetic overlap between 
schizophrenia and cognition than with other psychopathology, consistent with other 
evidence (Bulik-Sullivan et al. 2015). Whilst the variance explained for all phenotypes was 
small, this will likely increase as discovery sample sizes increase (Dudbridge 2013), though 
will be limited as the PRS does not capture CNV or rare SNP contributions to variance. 
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Our review also shows that genetic risk for schizophrenia is manifest in the population from 
early during development as a broad range of psychopathology, and that biological 
pathways identified from GWAS may have greater relevance for understanding negative-
symptom or other psychopathology rather than positive psychotic experiences as might be 
expected. 
 
Future gains from using the PRS approach may be greater if used for examining phenotypes 
that are more closely related to biological substrates (e.g. inflammatory markers or 
functional brain imaging), if scores are based on gene-pathways rather than the whole 
genome to enable the study of more specific biological effects, and if used to stratify 
individuals for study of treatment response. Future increases in size of discovery samples 
may also enable PRSs to make a meaningful contribution to risk prediction models, as has 
been shown for some non-psychiatric disorders (Chatterjee et al. 2016). 
 
4.5 Strengths and limitations  
 
We used a comprehensive search strategy to minimise missing eligible studies; however, 
studies not published in English-language journals will have been missed. We also included a 
broad range of outcomes, but our exclusion of studies reporting neuro-imaging results, 
based on the added complexity of summarizing these results means that we are not able to 
comment on how schizophrenia genetic risk relates to imaging phenotypes. Another 
strength is that studies were not limited to a specific sampling framework or research design 
(e.g. clinical samples or longitudinal studies), and this, along with the broad range of 
outcomes, enhanced our ability to inform how schizophrenia genetic risk is manifest. 
However, the inconsistency of reporting of results across studies meant that only a narrative 
approach to this review was feasible, and assessment of publication bias was not possible.   
 
There were several limitations identified in the studies included in this review, which made 
it problematic to place their findings within the context of other literature in the field. In 
particular, studies often failed to give a clear description of sample ascertainment, provided 
insufficient information to determine which comparison groups had a higher PRS, 
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inappropriately reported one-sided p-values, and did not provide standardised effect 
estimates or confidence intervals to enable comparison of effect sizes across studies. We 
therefore propose a reporting framework for future studies to employ which we believe 
would greatly assist researches synthesising data across such studies in the future (Table 1 
and Supplementary Table 5). 
 
4.6 Conclusions 
 
The PRS approach is an important approach used for capturing the contribution of genome 
wide common variation of complex diseases. To the best of our knowledge, this is the first 
review attempting to collate information on how the use of the PRS approach has informed 
our understanding of a variety of phenotypes associated with schizophrenia genetic risk. 
Our attempt to compare findings across studies leads us to propose a framework that can 
guide robust reporting of PRS associations.  
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